Characteristics of Extracellular Vesicles and Preclinical Testing Considerations Prior to Clinical Applications

Area of Science:

• Biotechnology
• Regenerative Medicine
• Drug Development

Background:

• Cell therapy products face challenges including storage instability, transportation issues, and toxicity concerns like tumorigenicity and immunogenicity.
• Extracellular vesicles (EVs) are emerging as promising therapeutic agents due to their inherent properties.
• Current non-clinical studies for EV therapeutic agent approval are complex and require further development.

Purpose of the Study:

• To review and summarize existing non-clinical safety studies on extracellular vesicles (EVs).
• To provide guidance for researchers developing EV-based therapeutic agents.
• To identify the need for novel methods in evaluating EV immunotoxicity and tumorigenicity.

Main Methods:

• Literature review of non-clinical studies on extracellular vesicles (EVs).
• Analysis of safety data, focusing on toxicity, immunogenicity, and tumorigenicity.
• Identification of current challenges and future directions in EV safety assessment.

Main Results:

• EVs avoid cell proliferation-related safety concerns like tumorigenicity.
• EV constituents may stimulate normal cell proliferation, necessitating rigorous safety evaluations.
• Existing non-clinical studies provide a foundation but highlight gaps in current safety assessment protocols.

Conclusions:

• Extracellular vesicles (EVs) present a viable alternative to cell therapies, mitigating risks associated with cell proliferation.
• Comprehensive non-clinical safety evaluations are crucial for the clinical translation of EV therapeutics.
• Development of standardized and advanced methods for assessing EV immunotoxicity and tumorigenicity is essential for regulatory approval.